Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions (Q44053877)

29 November 2017

title

Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions (English)

1 reference

29 November 2017

0 references

1 reference

7

1 reference

29 November 2017

3

Gabriel I Uwaifo

1 reference

29 November 2017

Jennifer R McDuffie

1

1 reference

29 November 2017

Karim A Calis

2

1 reference

29 November 2017

Nancy G Sebring

4

1 reference

29 November 2017

Erica M Fallon

5

1 reference

29 November 2017

Van S Hubbard

6

1 reference

29 November 2017

publication date

1 July 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

10

1 reference

29 November 2017

issue

7

1 reference

29 November 2017

page(s)

642-650

1 reference

Risks and consequences of childhood and adolescent obesity

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Aetiology of overweight and obesity in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Long-term maintenance of weight loss: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Treatment and follow-up of obesity in adolescent girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Evaluation of a weight management intervention program in adolescents with insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Pharmacokinetics of Highly Ionized Drugs II: Methylene Blue—Absorption, Metabolism, and Excretion in Man and Dog after Oral Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Increased skin pigment reduces the capacity of skin to synthesise vitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. A cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Beneficial effects of metformin in normoglycemic morbidly obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Weight control in adolescent girls: a comparison of the effectiveness of three approaches to follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

The effects of a children's summer camp programme on weight loss, with a 10 month follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Insulin and blood pressure during weight loss in obese adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Orlistat inhibits dietary cholesterol absorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

First clinical studies with orlistat: a short review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Treatment with orlistat reduces cardiovascular risk in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Evaluation of a new air displacement plethysmograph for measuring human body composition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

A comparison of air displacement plethysmography with three other techniques to determine body fat in healthy adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Comparison of air-displacement plethysmography with hydrostatic weighing and bioelectrical impedance analysis for the assessment of body composition in healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Comparison of air-displacement plethysmography, hydrodensitometry, and dual X-ray absorptiometry for assessing body composition of children 10 to 18 years of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Quantitation of serum tocopherols by high-performance liquid chromatography with fluorescence detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Development of a questionnaire for detecting potential adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.87

31 March 2020

Identifiers

DOI

10.1038/OBY.2002.87

1 reference

29 November 2017

1 reference